Community-acquired pneumonia (CAP) is a major cause of death worldwide. 1 The mortality attributed to CAP is high, despite adequate and early empiric antimicrobial treatment. 2 Empiric antibiotics must cover the main pathogens that cause pneumonia. Guidelines suggest the use of a b-lactam plus a macrolide (BL þ M), or a b-lactam plus a fluoroquinolone or a fluoroquinolone alone (FQ AE BL), as empiric treatment for hospitalized patients, but with fluoroquinolone monotherapy restricted to non-ICU patients. [3] [4] [5] Few randomized clinical trials (RCTs) have compared these antibiotic regimens, and the data available are the result of retrospective observational analyses. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] In many of these studies, combinations of a BL þ M showed better results than b-lactam monotherapy, even in patients with higher severity disease or when the responsible pathogen is resistant to macrolides. These benefits have been attributed to the immunomodulatory effect of macrolides in addition to their antimicrobial effect. 18, 19 However, fluoroquinolones also have an immunomodulatory effect and a similar antimicrobial spectrum for usual etiologic pathogens of CAP. 20 Pneumococcal pneumonia usually has a higher inflammatory response than pneumonia caused by other organisms, with some exceptions such as Legionella pneumophila 21 and toxin-producing Staphylococcus aureus. Therefore, we might expect a greater beneficial effect of including a macrolide in pneumococcal CAP compared with other etiologic groups. Indeed, several studies have shown the benefits of including macrolides in the treatment of pneumococcal CAP compared with monotherapy, particularly in the presence of bacteremia.
13, [22] [23] [24] The hypothesis of this study was that combining a b-lactam with a macrolide in patients with CAP resulted in decreased 30-day mortality, when compared with a quinolone-based regimen. We also aimed to test whether stratifying patients according to microbial etiology of CAP and the level of systemic inflammation was related to this benefit in mortality.
Methods

Study Design and Patients
We performed an observational study on a prospective cohort of consecutive patients with CAP who were admitted to the Hospital Clinic of Barcelona (January 1996 to December 2016).
Inclusion criteria were as follows: (1) adults $ 18 years old at diagnosis; (2) CAP confirmed by chest radiograph and consistent clinical manifestations (eg, fever, cough, sputum production, pleuritic chest pain); (3) patients with known etiology; and (4) patients who received a BL þ M or FQ AE BL as empiric treatment.
Exclusion criteria were as follows: (1) previous hospital admission for $ 48 hours in the preceding 14 days; (2) absence of complete clinical follow-up for 4 to 6 weeks; (3) severe immunosuppression, as in transplantation, HIV coinfection, or in patients receiving chemotherapy or other immunosuppressive drugs (> 20 mg of prednisone-equivalent per day for 2 weeks or more); and (4) empiric treatment with combinations other than those described above.
Ethics Statement
The Ethics Committee of the Hospital Clinic of Barcelona approved the study for the purpose of publication (Register: 2009/5451). The need for written informed consent was waived because of the noninterventional design. Patients' identity remained anonymous.
Data Collection
The comorbidities were recorded from the medical records. Clinical, laboratory, and radiographic characteristics were recorded on admission (described in detail in the online article). During hospitalization, the following data were recorded: length of stay, admission to the ICU, need for mechanical ventilation (invasive or noninvasive), and 30-day mortality.
Severe CAP was defined according to American Thoracic Society/ Infectious Diseases Society of America guidelines. 3 Pneumonia Severity Index (PSI), 25 Sequential (previously, Sepsis-Related) Organ Failure Assessment (SOFA), 26 and CURB-65 27 scores were used to stratify cases according to severity.
Microbiologic Evaluation
Microbiologic examination is described in detail in the online article (e-Appendix 1).
Definitions
We separated the patients according to initial antimicrobial treatment into two groups: patients who received a BL þ M, and patients who received an FQ AE BL.
(Chlamydophila pneumoniae, Chlamydia psittaci, Coxiella burnetii, Mycoplasma pneumoniae, and Legionella pneumophila) and patients with other etiology (organisms not included in previous groups, or polymicrobial etiology).
We defined patients with a high inflammatory response as those with a C-reactive protein (CRP) level greater than 15 mg/dL at admission, based on the results of a previous study. 28 Appropriateness of empiric antimicrobial treatment in patients was defined when the isolated pathogens were susceptible in vitro to one or more of the antimicrobials administered.
Outcomes
The main outcome was 30-day all-cause mortality.
Statistical Analysis
We report the number and percentage of patients for categorical variables, the median and interquartile range (IQR) for continuous variables with a nonnormal distribution, and the mean and standard deviation for those with a normal distribution. Categorical variables were compared using the c 2 test or the Fisher exact test. Continuous variables were compared using the t test or the nonparametric Mann-Whitney test.
Logistic regression analyses 29 were used to examine the associations between 30-day mortality and risk factors. In the first step, each risk factor was tested individually. In the second step, all risk factors that showed an association in the univariate model (P < .10) were added into the multivariable model. Finally, a backward stepwise selection (P in < .05, P out > .10) was used to determine factors associated with 30-day mortality. If two independent variables were highly correlated (r > jAE 0.30j), the variable with the largest variance was excluded from the multivariable analyses. 30 The OR and 95% CI were calculated.
A propensity score for patients receiving antimicrobial treatment was developed 31 because the antimicrobial treatment was not randomly administered to these patients, resulting in a potential confounding factor and selection bias. The propensity score was determined, irrespective of the outcome, through a multinomial logistic regression to predict the influence of 18 predetermined variables on the use of antimicrobial treatment. Variables were chosen for inclusion in the propensity score calculation according to the methods of Brookhart et al 32 and included variables associated with antimicrobial use and outcome. The score was finally entered as a continuous variable in the multivariable logistic regression analysis for 30-day mortality, together with the antimicrobial treatment, the microbial etiology, the year of occurrence of pneumonia, and admission to the ICU. As sensitivity analyses, the same analyses were performed on the subset of patients with pneumococcal CAP, and for patients with CRP > 15 mg/dL.
We used the multiple imputation method 33 for missing data in the multivariable analyses. The level of significance was set at .05 (twotailed). All analyses were performed with SPSS Statistics version 23.0 (IBM, Armonk, NY).
Results
Patient Characteristics
Of the 6,442 patients with CAP admitted during the study period, 1,715 (28%) were included in the present study; the main exclusion criterion was unknown etiology in 3,841 patients (60%) (Fig 1) . Nine hundred and thirty-two patients (54%) received empiric antibiotic treatment with a BL þ M, and 783 patients (46%) received an FQ AE BL.
The baseline characteristics of the two groups are summarized in Table 1 . Patients who received a BL þ M had more frequent chronic pulmonary disease and were chestjournal.org more often former or current smokers; they had less frequent neurologic disease, previous influenza vaccination, nursing home residence, or previous antibiotic therapy.
The main causal organism was Streptococcus pneumoniae in both groups (Fig 1) . Detailed information on microbial etiology is shown in Table 2 . High inflammatory response (CRP > 15 mg/dL) at admission was present in 534 patients (70%) with pneumococcal CAP, 117 patients (55%) with atypical etiology, and 341 patients (46%) with another etiology.
We found no differences in severity scores such as CURB-65, PSI, or SOFA; however, patients who received an FQ AE BL were more frequently admitted to the ICU, and more often required noninvasive ventilation, or presented with severe CAP, particularly septic shock. No differences were observed in the requirement for invasive mechanical ventilation (Table 3 ).
Antibiotic Treatment
Among 1,715 patients, 1,387 (81%) were treated with a b-lactam; of these, 1,209 (87%) received ceftriaxone.
Patients treated with a BL þ M received azithromycin in 758 cases (81%), erythromycin in 111 cases (12%), and clarithromycin in 63 cases (7%).
In patients treated with an FQ AE BL, 455 (58%) received a fluoroquinolone in combination with a b-lactam. In this group 767 patients (98%) received levofloxacin, 12 patients (1.5%) received ciprofloxacin, and 4 patients (0.5%) received moxifloxacin; all patients given ciprofloxacin received that treatment in combination with a b-lactam.
Outcomes
Patients receiving a BL þ M had lower crude 30-day mortality compared with patients who received an FQ AE BL (5% vs 8%; P ¼ .015) ( Table 4) . Similar results were observed in patients with a high inflammatory response (BL þ M, 3% vs FQ AE BL, 8%; P < .001) and for patients with pneumococcal CAP (BL þ M, 4% vs FQ AE BL, 9%; P ¼ .004). The greatest difference in mortality was observed in patients with both a high inflammatory response and pneumococcal CAP (BL þ M, 2% vs FQ AE BL, 10%; P # .001). No differences in 30-day mortality between both groups were observed in patients with atypical or other etiologies. Moreover, we grouped all patients without pneumococcal CAP and without a high inflammatory response and again no significant differences were observed. Percentages calculated on nonmissing data.
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In the overall population and specifically in patients with pneumococcal pneumonia, the propensity-adjusted multivariable analysis did not show any significant association between the antibiotic treatment and 30-day mortality (e- Tables 1, 2 ; e- Fig 1) ; however, for the population with a high inflammatory response we observed a significant interaction between antimicrobial treatment and etiology, specifically for patients with pneumococcal CAP, who also received antibiotic treatment with a BL þ M (adjusted OR, 0.28; 95% CI, 0.09-0.92; P ¼ .036) ( Table 5 ). The multivariable analysis adjusted by propensity score for 30-day mortality also showed that PSI risk classes IV and V, acute respiratory distress syndrome, septic shock, and inappropriate treatment were independent risk factors for death. The area under the receiver-operating characteristic curve was 0.85 (95% CI, 0.80-0.89) (e- Fig  1) for the model of 30-day mortality.
Internal validation of the logistic regression model for patients with high inflammatory response was conducted by bootstrapping with 1,000 samples (e- 
Discussion
In this well-characterized cohort of patients with CAP we compared the effect of two types of empiric antibiotic treatments, BL þ M and FQ AE BL, on 30-day mortality. After adjusting for confounders, BL þ M did not protect for mortality in the overall population; however, our analyses revealed that the combination of a BL þ M compared with an FQ AE BL had an independent association with less 30-day mortality only in patients with pneumococcal CAP and in those with a high inflammatory response (CRP > 15 mg/dL), with the greatest benefit in those with both factors present. No differences in mortality were observed between groups of patients with other microbial etiologies and high inflammatory response.
Several observational studies have shown that the combination of a b-lactam with a macrolide is better alone is less clear. In this study we compared these combinations in various subgroups and found differences in favor of the macrolide combination in a specific group of patients. Benefits in pneumococcal bacteremic CAP were previously reported for a BL þ M combination even though, when compared with fluoroquinolone-based therapies, no benefits were observed 13 ; however, this study did not look at the inflammatory status. A recent study has shown better outcomes in patients who received macrolide therapy and presented with bacteremic pneumonia. 34 Moreover, the most common cause of bacteremic pneumonia was pneumococcus in 74% of patients, and although the authors did not look at CRP levels, patients with invasive pneumococcal CAP usually presented greater levels of CRP. 35 A meta-analysis that compared the combination of a b-lactam with a macrolide vs a b-lactam with a fluoroquinolone showed no significant differences in short-term mortality (adjusted risk ratio, 1.26; 95% CI, 0.95-1.67; I 2 , 43%) 36 ; and another meta-analysis showed that ceftriaxone combination therapy was similar in terms of treatment success compared with fluoroquinolone monotherapy in patients with CAP. 37 The study by Postma et al 6 showing mortality benefit regardless of whether the CRP level was above or below 15 mg/dL. 38 CRP is an inflammatory marker that can predict poor outcomes and treatment failure in patients with CAP or sepsis for other causes, and could be used for evaluate response to treatment. [39] [40] [41] As in previous studies on adjuvant treatments in CAP, 28, 42 we looked at specific populations in whom a BL þ M could have a beneficial effect. Furthermore, a recent report by the US National Heart, of the impact on pneumococcal CAP with a high inflammatory response is the fact that macrolides not only inhibit bacterial protein synthesis but are also potent inhibitors of the production of pneumolysin, even at subinhibitory concentrations. 48, 49 The combined impact on bacteria and on the host response may explain our findings.
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The main limitation of this study is that it was performed at a single center, and so the results should be confirmed in other databases or in prospective RCTs. Another limitation is that we observed that patients who received fluoroquinolones alone or in combinations had more severe disease and were admitted to the ICU more frequently; this may represent a bias in our study, given that physicians, including the ICU team, more often used fluoroquinolones in patients with more severe disease. We tried to address this issue by adjusting all the multivariable analyses by ICU admission. In addition, the etiology of CAP identified in our study showed a high frequency of pneumococcal infection, a finding that is at variance with the data in a large study from the United States. 50 Our results suggest the need for a new RCT in a population with S. pneumoniae and high inflammatory response to evaluate the mortality benefit of adding a macrolide to a b-lactam. The strengths of our study are that we analyzed a large database with a well-characterized population with microbiologic data. In addition, we compared combinations of a b-lactam with either a macrolide or a fluoroquinolone; both regimens are active against the most common pathogens causing CAP, and both macrolides and fluoroquinolones have immunomodulatory activity.
In conclusion, the combination of a b-lactam with a macrolide was associated with decreased mortality in patients with pneumococcal CAP and in patients with high systemic inflammatory response. When both factors occurred together, BL þ M combinations were protective for mortality in the multivariate analysis.
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